GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XIX Conference in San Diego on Tuesday, October 21, 2025, at 1:00 p.m. PT (4:00 p.m. ET). LD Micro Main Event XIX ConferencePresentation Date: Tuesday, October 21, 2025Presentation Time: 1:00 p.m. PT (4:00 p.m. ET)Webcast: Click here Elutia management w ...

TRUMP MARKET MOVES: Will These Be Next U.S. Equity Stakes? On Tuesday, TransMedics Group (TMDX) stock earned an upgrade to its Relative Strength (RS) Rating, from 69 to 73. Â Can You Really Time The Stock Market? This proprietary rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database. Over 100 years of… IBD Videos Get market updates, educational videos, webinars, and stock analysis. Get Started Related new ...

Johnson & Johnson (NYSE:JNJ) is included among the 12 Reliable Dividend Stocks for Maximum Income. Johnson & Johnson’s (JNJ) Strong Dividend Track Record and Focus on Innovation Johnson & Johnson (NYSE:JNJ) operates as a global healthcare lea‍de‌r, focusing p‌rimari​ly on pharmaceuticals and medi⁠cal d‍evices. Its⁠ operations are di‍vided into two main se⁠gment​s: Innovative Me⁠dicine, which de⁠velops and markets prescription drugs, and MedTech, which produces medi⁠cal d‌evic‌es. Up until 2023, Johnson ...

Edwards Lifesciences Corporation (NYSE: EW ) was founded in 1958 and is based in Irvine, CA. It is a leader in designing and commercializing innovative technologies for the treatment of advanced cardiovascular diseases. Its main productsI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I belie ...

Company Overview - Edwards Lifesciences Corporation, founded in 1958, is based in Irvine, CA, and is a leader in designing and commercializing innovative technologies for the treatment of advanced cardiovascular diseases [1]. Investment Philosophy - The investment philosophy emphasizes the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good and bad times yields the greatest rewards [1]. - The approach to wealth creation involves the slow accumulation of high-quality assets, mixed with high-risk/high-reward opportunities and transformative technologies [1]. Educational Background - The individual has over 20 years of teaching experience at the college/university level and holds a PhD from Brunel University, indicating a strong academic background [1].

Core Insights - Johnson & Johnson reported strong third-quarter earnings with earnings per share of $2.80 and revenue of approximately $23.99 billion, both exceeding estimates [1][6] - The company has raised its 2025 revenue forecast to between $93 billion and $93.5 billion, supported by a 15.7% increase in adjusted earnings per share compared to the previous year [2][6] - A strategic decision was made to spin off its orthopedics business into a standalone company, allowing JNJ to focus on its core operations [3][6] Financial Metrics - Johnson & Johnson has a price-to-earnings (P/E) ratio of approximately 19.99, indicating market valuation of its earnings [4] - The price-to-sales ratio is about 4.98, reflecting the market's valuation of its revenue [4] - The enterprise value to sales ratio stands at around 5.33, suggesting the market's valuation of the company's total value in relation to its sales [4] Financial Health - The company has a debt-to-equity ratio of approximately 0.65, indicating a balanced use of debt and equity [5] - A current ratio of around 1.01 demonstrates the company's ability to cover short-term liabilities with short-term assets [5]

Key Takeaways STXS partners with CardioFocus to create a robotic PFA system for cardiac arrhythmia treatment.The collaboration merges robotic precision with advanced PFA technology for safer, faster ablations.STXS gains access to the expanding PFA market, enhancing its robotics portfolio and growth potential. Stereotaxis (STXS) recently partnered with CardioFocus to develop the first robotic Pulsed Field Ablation (PFA) system for treating cardiac arrhythmias. The collaboration brings together Stereotaxis’ r ...

Johnson & Johnson (J&J) has made the latest slimming down move across its company in recent years, saying it plans to separate its orthopaedics business into a new stand-alone company. While few details were shared on the spinoff, J&J said the new business will be named DePuy Synthes. The decision comes despite modest growth for the business, which already includes DePuy Synthes as one of its components. The unit, which includes artificial hip and knee devices, grew 2.4% this quarter. J&J acquired Switz ...

Key Takeaways J&J reported Q3 EPS of $2.80, up 15.7%, with revenue rising 6.8% to $24 billion.Strong results in Innovative Medicines and MedTech units drove J&J to raise 2025 sales guidance.J&J will spin off its Orthopaedics business, DePuy Synthes, to focus on faster-growing MedTech areas.Johnson & Johnson’s (JNJ) third-quarter 2025 earnings came in at $2.80 per share, which beat the Zacks Consensus Estimate of $2.77. Earnings rose 15.7% from the year-ago period.Adjusted earnings exclude intangible amortiz ...

Apyx Medical (NasdaqGS:APYX) Conference Call Summary Company Overview - **Company**: Apyx Medical Corporation - **Event Date**: October 14, 2025 - **Key Product**: Apyx One Console, a body contouring system Industry Insights - **Market Context**: The surgical aesthetics market is evolving, particularly due to the rise of GLP-1 therapies for weight loss, leading to increased demand for body contouring solutions among post-weight loss patients [4][6] - **Market Size**: GLP-1 therapies are projected to exceed $100 billion by 2030, with 44% of users spending between $2,000 and $5,000 on aesthetic procedures, a 25% increase in spending [6] - **Patient Demographics**: 63% of GLP-1 users are new to aesthetics post-weight loss, indicating a growing patient population for plastic surgeons [6] Product Launch and Performance - **Product Launch**: Apyx One Console received approval in May 2025 and has undergone a successful soft launch with key surgeons across the U.S. [5][4] - **Sales Update**: Commercial sales began in September 2025, with ongoing sales in Q4 2025. A 510(k) submission for the power-assisted handpiece is expected to receive clearance in Q1 2026 [5][6] - **Technological Advancements**: The Apyx One Console integrates multiple technologies, including ultrasound-assisted liposuction and Renuvion for skin tightening, designed based on feedback from leading plastic surgeons [10][12] Clinical Insights - **Surgical Trends**: There has been a decline in liposuction procedures by 10.7%, while surgical lifts have increased by over 20%, reflecting the need for more complex surgical interventions for patients with lax skin [7][8] - **Patient Concerns**: 72% of GLP-1 users report loose skin as their primary concern, with 57% seeking treatment within six months post-weight loss [9] Feedback and Reception - **Surgeon Feedback**: Surgeons have expressed high satisfaction with the Apyx One Console, describing it as revolutionary and comparing it to luxury vehicles like Ferraris and Lamborghinis [13][14] - **Clinical Efficiency**: The integration of technologies in the Apyx One Console has led to improved surgical efficiency, with reduced procedure times and enhanced patient outcomes [32][51] Future Outlook - **Market Positioning**: Apyx Medical is well-positioned to capture growth in the surgical aesthetics market, particularly among post-weight loss patients seeking body contouring solutions [6][4] - **Anticipated Developments**: The upcoming launch of the power-assisted handpiece is expected to further enhance the capabilities of the Apyx One Console, attracting more surgeons and patients [65][66] Additional Insights - **Patient Experience**: The Apyx One Console aims to simplify the surgical process, reducing the need for multiple devices and improving the overall patient experience [21][22] - **Technological Trust**: Surgeons have shown a willingness to adopt the Apyx One Console based on the company's commitment to evidence-based medicine and the collaborative development process involving top surgeons [66][68] This summary encapsulates the key points discussed during the Apyx Medical conference call, highlighting the company's strategic positioning, product innovations, and the evolving landscape of the surgical aesthetics market.